PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10904980

[Current data on topiramate].

J L Herranz
View original source ↗Export metadata ↓

Abstract

OBJECTIVES: To review current knowledge regarding the mechanisms of action, pharmacokinetics, clinical efficacy and the tolerance of topirimate (TPM) and describe the Spanish experience of the use of this drug in 224 patients of all ages. DEVELOPMENT: TPM is a new drug which affects practically all the mechanisms involved in the production of epileptic seizures, which means that it is a broad-spectrum antiepileptic drug. After reviewing the mechanisms of action and pharmacokinetic characteristics of TPM, we consider the efficacy of the drug in 224 patients of all ages with all types of epileptic seizures. CONCLUSIONS: In patients of all ages with uncontrolled epileptic seizures treated with TPM, the frequency of their seizures was reduced by over 50% in 78% of the patients and the seizures were abolished in 25% of the total cases. The drug was generally well tolerated. Side-effects leading to suspension of the drug occurred in only 5% of the cases. TPM is an effective drug which is well tolerated in patients of all ages and with all kinds of epilepsy.

Explore related subjects

AnticonvulsantsChild, PreschoolEpilepsyFructoseHumansInfantTopiramateJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J L Herranz. 2000. [Current data on topiramate].. https://pubmed.ncbi.nlm.nih.gov/10904980/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗